Jeff Liter, CEO of Luminary, discusses his company’s approach to CAR-T therapies and why the developing Saudi market has ...

Due to popularity of the medications, GLP-1s were in short supply up until recently. Obesity is a common issue among ...

The supplemental premarket approval application is supported by Phase III data, which showed significant improvements in neck ...

Gamifant marks the first-ever FDA-approved treatment for both adult and pediatric patients with hemophagocytic ...

Under terms of the deal, AbbVie will acquire Capstan’s lead asset, CPTX2309—an in vivo anti-CD19 CAR T-cell therapy in Phase ...